Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)

HKG:2348 Revenue

Dawnrays Pharmaceutical (Holdings) had revenue of 545.84M CNY in the half year ending June 30, 2026, a decrease of -5.47%. This brings the company's total for the last twelve months to 1.15B, up 2.96% year-over-year. In the year 2025, Dawnrays Pharmaceutical (Holdings) had annual revenue of 1.23B with 16.09% growth. That makes Dawnrays Pharmaceutical (Holdings) the 18,730th largest company in the world by revenue and 1,093rd in Hong Kong.

• Revenue (ttm): 1.15B CNY
• Revenue Growth: +2.96%
• P/S Ratio: 1.05
• Revenue / Employee: 1.07M CNY
• Employees: 1,074
• Market Cap: 1.39B HKD

Revenue Chart

Chart

Chart

* This company reports financials in CNY.

Revenue by Segment

By Segment

Chart

• Finished Drugs 1.16B 86.8%
• Intermediates and Bulk Medicines 177.27M 13.2%

By Geography

Chart

• Chinese Mainland 1.22B 98.8%
• Other Countries 14.45M 1.2%

Fiscal year ended Dec 31, 2025 See the full HKG:2348 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.23B	170.56M	16.09%
Dec 31, 2024	1.06B	-90.84M	-7.89%
Dec 31, 2023	1.15B	-126.54M	-9.90%
Dec 31, 2022	1.28B	112.53M	9.66%
Dec 31, 2021	1.17B	140.89M	13.75%

Data Source: S&P Global Market Intelligence Last updated: Sep 17, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 29, 2026

Data Sources Report a data error